UNITED STATES
                   SECURITIES AND EXCHANGE COMMISSION
                          Washington, D.C. 20549

                               SCHEDULE 13D


                Under the Securities Exchange Act of 1934
                            (Amendment No.  12)*

                          RESPONSE ONCOLOGY, INC.
                              (Name of Issuer)

                      Common Stock $.01 Par Value (1)
                      (Title of Class of Securities)

                                761232-107
                              (CUSIP Number)

               Lathrop M. Gates, 2345 Grand Blvd., Suite 2800,
                   Kansas City, MO  64108, (816) 292-2000
                (Name, Address and Telephone Number of Person
              Authorized to Receive Notices and Communications)

                                 07/25/97
            (Date of Event which Requires Filing of this Statement)

If the reporting person has previously filed a statement on 
Schedule 13G to report the acquisition which is the subject of 
this Schedule 13D, and is filing this schedule because of Rule 
13d-1(b) (3) or (4), check the following box.  ______

Check the following box if a fee is being paid with this 
statement.  ______ (A fee is not required only if the reporting 
person: (1) has a previous statement on file reporting 
beneficial ownership of more than five percent of the class of 
securities described in Item 1; and (2) has filed no amendment 
subsequent thereto reporting beneficial ownership of five 
percent or less of such class.)  (See Rule 13d-7).

Note:  Six copies of this statement, including all exhibits, 
should be filed with the Commission.  See Rule 13d-1 (a) for 
other parties to whom copies are to be sent.

                                                   
____________________
*The remainder of this cover page shall be filled out for a 
reporting person's initial filing on this form with respect to 
the subject class of securities, and for any subsequent 
amendment containing information which would alter the 
disclosures provided in a prior cover page.


The information required on the remainder of this cover page 
shall not be deemed to be "filed" for the purpose of Section 18 
of the Securities Exchange Act of 1934 ("Act") or otherwise 
subject to the liabilities of that section of the Act but shall 
be subject to all other provisions of the Act (however, see the 
Notes).

(1)     Name of Reporting Person
          S.S. or I.R.S. Identification No. of Above Person

          Seafield Capital Corporation
          43-1039532

(2)     Check the Appropriate Box                      (a)_____   
          if a Member of a Group*                      (b)_____

(3)     SEC Use Only

(4)     Source of funds*
          Not Applicable

(5)     Check Box if Disclosure of Legal Proceedings is 
          Required Pursuant to Items 2(d) or 2(e)         _____

(6)      Citizenship or Place of Organization
           Missouri

           Number of Shares                 (7) Sole Voting Power 
           beneficially Owned                   -0-
           by Each Reporting
           Person With                      (8) Shared Voting Power
                                                -0-
                                            (9) Sole Dispositive Power
                                                -0-
                                           (10) Shared Dispositive Power
                                                -0-

(11)     Aggregate Amount Beneficially Owned By Each Reporting Person
            -0-

(12)     Check Box if the Aggregate Amount in Row (11) Excludes Certain
         Shares*              __X___


(13)     Percent of Class Represented by Amount in  Row (11) 
         0%

(14)     Type of Reporting Person*       
         CO  

*  See Instructions before Filling Out!



Item 1.      Security and Issuer.

           This Amendment No. 12 ("Amendment No. 12") to  
Schedule 13D concerns the common stock, par value $.01 per 
share ("Common Stock") of Response Oncology, Inc. (formerly 
named Response Technologies, Inc.) ("Response"), whose 
principal executive offices are at 1775 Moriah Woods Boulevard, 
Memphis, Tennessee  38117.   Amendment No. 12  amends an 
original report (the "Original Report") on Schedule 13D 
respecting a purchase of shares of Common Stock on October 31, 
1990, as amended by Amendment No. 1 to Schedule 13D, dated 
August 2, 1991 ("Amendment No. 1"), Amendment No. 2 to Schedule 
13D, dated November 11, 1991 ("Amendment No. 2"), Amendment No. 
3 to Schedule 13D, dated June 9, 1992  ("Amendment No. 3"), 
Amendment No. 4 to Schedule 13D dated, August 4, 1992  
("Amendment No. 4"), Amendment No. 5 to Schedule 13D, dated May 
13, 1993 ("Amendment No. 5"),  Amendment No. 6  to Schedule 
13D, dated February 17, 1995 ("Amendment No. 6"),  Amendment 
No. 7 to Schedule 13D, dated June 24, 1996 ("Amendment No. 7"), 
Amendment No. 8 to Schedule 13D, dated September 4, 1996 
("Amendment No. 8"), Amendment No. 9 to Schedule 13D, dated 
October 16, 1996 ("Amendment No. 9"), Amendment No. 10 to 
Schedule 13D, dated March 7, 1997 ("Amendment No. 10") and 
Amendment No. 11 to Schedule 13D, dated July 10, 1997 
(Amendment No. 11) (collectively, Amendments No.1, No. 2, No.3, 
No. 4, No. 5, No.6, No. 7, No. 8, No. 9, No. 10 and No. 11 are 
sometimes referred to as the "Prior Amendments").  The Issuer 
is the same Issuer referred to in the Original Report and in 
the Prior Amendments; the current name of the Issuer reflects a 
change effective November 1995.  The Common Stock is  the same 
class of stock reported on in the Original Report and in the 
Prior Amendments; the par value of the Common Stock was changed 
in November 1995 as a result of a 1 for 5 reverse stock split.

Item 2.    Identity and Background.

           This report is filed by Seafield Capital Corporation 
("Seafield") (formerly named BMA Corporation).  Seafield is a 
Missouri corporation; the address of its principal executive 
office is 5000 West 95th Street, Suite 260, P.O. Box 7568, 
Shawnee Mission, Kansas 66207.   Seafield is a holding company 
whose principal interest now is its 82% owned subsidiary, 
LabOne, Inc. (formerly named Home Office Reference Laboratory, 
Inc.), a provider of clinical, substance abuse and insurance 
laboratory testing services whose offices are located at 10310 
West 84th Terrace, Lenexa, Kansas  66214.  Seafield also owns  
certain short-term and intermediate-term investment grade 
securities.

             Set forth in Schedule 1 hereto are the names, 
business addresses and principal occupations or employment of 
the executive officers and directors of Seafield.  Each person 
listed on Schedule 1 is a United States citizen.

             During the past five years, neither Seafield nor 
to its  knowledge, any of the persons identified in Schedule 1 
has been  (i) convicted in a criminal proceeding, or (ii) a 
party to a civil proceeding of a judicial or administrative 
body as a result of which such person was or is subject to  a 
judgment, decree or final order enjoining future violations of, 
or prohibiting or mandating activities subject to, federal or 
state securities laws or finding any violation with respect to 
such laws. 

Item 3.     Source and Amount of Funds or Other Consideration.

Not Applicable.

Item 4.     Purpose of the Transaction.

On June 3, 1997, Response filed a Registration Statement 
with the Securities and Exchange Commission ("SEC") respecting, 
among other things, a distribution to Seafield shareholders of 
all shares of Response Common Stock owned by Seafield.  The 
Registration Statement was filed pursuant to certain 
registration rights under Section 5.1 of that certain 
Securities Purchase Agreement dated September 26, 1990 between 
Response and Seafield (the "Securities Purchase Agreement").  
On July 1, 1997, that Registration Statement was declared 
effective by the SEC and Seafield's Board of Directors declared 
a dividend to its shareholders of record as of July 11, 1997, 
payable July 25, 1997, in the form of all shares of Response 
Common Stock owned by Seafield; the distribution ratio will be 
approximately 1.24 shares of Response Common Stock for each 
share of Seafield common stock outstanding (i.e., 6,489,103).  
On July 25, 1997, all shares of Response Common Stock owned by 
Seafield were distributed to Seafield shareholders; provided 
that a small number of those Response shares were sold by the 
Distribution Agent for the distribution (with the proceeds 
being remitted to Seafield shareholders) in order to avoid 
distributing fractional shares to Seafield shareholders.  As a 
result, Seafield no longer owns any shares of Response Common 
Stock. 
          
           Seafield has no plans or proposals which relate to 
or would result in (i) the acquisition by any person of 
additional securities of Response, or the disposition of 
securities of Response; (ii) an extraordinary corporate 
transaction involving Response or any of its subsidiaries; 
(iii) a sale or transfer of a material amount of assets of 
Response or any of its subsidiaries; (iv) any change in the 
present board of directors or management of Response; (v) any 
material change in the present capitalization or dividend 
policy of Response; (vi) any other material change in 
Response's business or corporate structure; (vii) any change in 
Response's charter or bylaws which may impede the acquisition 
of control of Response by any person; (viii) causing a class of 
Response's securities to be delisted from a national securities 
exchange or to cease to be authorized to be quoted in an inter-
dealer quotation system of a registered national securities 
association; (ix) a class of equity securities of Response 
being eligible for termination of registration pursuant to 
Section 12(g)(4) of the Securities Exchange Act of 1934; or 
(x) any act similar to any of those enumerated above.

Item 5.     Interest in Securities of the Issuer.

           (a), (b) and (c).

Seafield beneficially owns  no shares of Response Common 
Stock.  All shares previously owned by Seafield had been 
acquired more than 60 days before the distribution by Seafield 
to its shareholders described above.  Said distribution was 
effected on July 25, 1997.

           Certain of the persons named in Schedule 1 are known 
by Seafield to beneficially own shares of Response stock.  To 
Seafield's knowledge, these shares were acquired by such 
persons solely for investment purposes and  such persons have 
sole power to vote and dispose of such shares.  Seafield 
disclaims any beneficial ownership in any of such shares.  The 
persons known to Seafield to beneficially own such shares and 
the number of such shares beneficially owned by such persons 
(with an indication of the shares which there is a right to 
acquire) are as follows:

         Name                Number of Shares

    Joseph T. Clark                   213,349
    W. Thomas Grant, II                11,400
    P. Anthony Jacobs                  15,400
    James R. Seward                    15,400
                           
Of the number of shares shown above, the following numbers 
consist of options which the indicated individuals have the 
right to exercise either presently or within 60 days:  for  
Joseph T. Clark, 177,652; for W. Thomas Grant II, 11,000; for 
P. Anthony Jacobs, 11,000 and for James R. Seward, 11,000.

           (d) and (e)     Not Applicable.

Item 6.	Contracts, Arrangements, Understanding or 
Relationships with Respect to Securities of the Issuer.

           No longer applicable.

Item 7.     Exhibits.

            None.





SIGNATURE

After reasonable inquiry and to the best of my knowledge 
and belief, I certify that the information set forth in this 
statement is true, complete and correct.


SEAFIELD CAPITAL CORPORATION


By:      /s/  Steven K. Fitzwater                
      -----------------------------------
      Steven K. Fitzwater, Vice President


Date:	August 28, 1997
           

         


SCHEDULE 1


          Directors of Seafield Capital Corporation

          Name, Occupation and Business Address

Lan C. Bentsen, Managing Partner 
Remington Partners (investments)
3040 Post Oak Boulevard, Suite 200
Houston, Texas  77056

John C. Gamble, Managing Partner
Allen, Matkins Leck, Gamble and Mallory (law)
18400 Von Karmen, 4th Floor
Irvine, California  92715

William D. Grant, Retired
One Ward Parkway, Suite 130
Kansas City, Missouri  64112

W. Thomas Grant, II, Chairman of the Board and Chief Executive 
Officer/Seafield Capital Corporation; Chairman of the Board, 
President and Chief Executive Officer/LabOne, Inc.
5000 West 95th Street, Suite 260
Post Office Box 7568
Shawnee Mission, Kansas 66207

Michael E. Herman, Chairman
Ewing Marion Kauffman Foundation
4900 Oak Street
Kansas City, Missouri  64112

P. Anthony Jacobs, President and Chief Operating Officer
Seafield Capital Corporation
5000 West 95th Street, Suite 260
Post Office Box 7568
Shawnee Mission, Kansas 66207

David W. Kemper, Chairman, President and Chief Executive 
Officer
Commerce Bancshares, Inc. (banking)
1000 Walnut Street, 18th Floor
Kansas City, Missouri  64106

John H. Robinson, Jr., Managing Partner
Black & Veatch (design and construction)
11401 Lamar Avenue
Overland Park, Kansas  66211-1598

James R. Seward, Executive Vice President and Chief Financial 
Officer
Seafield Capital Corporation
5000 West 95th Street, Suite 260
Post Office Box 7568
Shawnee Mission, Kansas 66207

Dennis R. Stephen, Chief Operating Officer
Tennessee Farmers Insurance Companies (insurance)
Post Office Box 307
Columbia, Tennessee  38401

          Executive Officers of Seafield Capital Corporation

           Name,  Position and Business Address

W. T. Grant, II
Chairman of the Board and Chief Executive Officer/Seafield 
Capital Corporation
Chairman of the Board, President and Chief Executive 
Officer/LabOne, Inc.
5000 West 95th Street, Suite 260
Post Office Box 7568
Shawnee Mission, Kansas 66207

P. Anthony Jacobs, President and Chief Operating Officer
Seafield Capital Corporation
5000 West 95th Street, Suite 260
Post Office Box 7568
Shawnee Mission, Kansas 66207

James R. Seward, Executive Vice President and Chief Financial 
Officer
Seafield Capital Corporation
5000 West 95th Street, Suite 260
Post Office Box 7568
Shawnee Mission, Kansas 66207

Steven K. Fitzwater, Vice President, Chief Accounting Officer 
and Secretary
Seafield Capital Corporation
5000 West 95th Street, Suite 260
Post Office Box 7568
Shawnee Mission, Kansas 66207

Joseph T. Clark, President and Chief Executive Officer
Response Oncology, Inc.
1775 Moriah Woods Boulevard
Memphis, Tennessee  38117